Mereo BioPharma Group plc (MREO) — Analyst outlook / Analyst consensus target is. Based on 8 analyst ratings, the consensus is bullish — 5 Buy, 3 Hold.
The consensus price target is $0.83 (low: $0.50, high: $1.00), representing an upside of 152.3% from the current price $0.33.
Analysts estimate Earnings Per Share (EPS) of $-0.06 and revenue of $0.02B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.29 vs est $-0.06 (missed -372.1%). 2025: actual $-0.26 vs est $-0.06 (missed -366.7%). Analyst accuracy: 21%.
MREO Stock — 12-Month Price Forecast
$0.83
▲ +152.28% Upside
Average Price Target
Based on 8 Wall Street analysts offering 12-month price targets for Mereo BioPharma Group plc, the average price target is $0.83, with a high forecast of $1.00, and a low forecast of $0.50.
The average price target represents a +152.28% change from the last price of $0.33.
Highest Price Target
$1.00
Average Price Target
$0.83
Lowest Price Target
$0.50
MREO Analyst Ratings
Buy
Based on 8 analysts giving stock ratings to Mereo BioPharma Group plc in the past 3 months
EPS Estimates — MREO
21%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$0.29
vs Est –$0.06
▼ 78.8% off
2025
Actual –$0.26
vs Est –$0.06
▼ 78.6% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — MREO
0%
Analyst Accuracy
Inaccurate
1 year compared
Actual vs Estimate
2025
Actual $0.001B
vs Est $0.006B
▼ 1,153.3% off
Revenue Trend
Revenue has been relatively flat. Analysts forecast significant revenue growth ahead.
